key: cord-0817813-k7wr1lo4
authors: Bal, A.; Trabaud, M.-A.; Fassier, J.-B.; Rabilloud, M.; Saker, K.; Langlois, C.; Guibert, N.; d'Aubarede, C.; Paul, A.; Alfaiate, D.; Massardier, A.; Pitiot, V.; Morfin, F.; Lina, B.; Pozzetto, B.; Trouillet-Assant, S.
title: Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralisation and commercial assays
date: 2020-12-09
journal: nan
DOI: 10.1101/2020.12.08.20245811
sha: a8c714bfbb2bc0fe50323730b94b473feee84e3a
doc_id: 817813
cord_uid: k7wr1lo4

We conducted a prospective study in healthcare workers (n=296) of the University Hospital of Lyon, France. Serum samples (n=296) collected six months after disease onset were tested using three commercial assays: the Wantai Ab assay detecting total antibodies against the receptor binding domain (RBD) of the S protein, the bioMerieux Vidas assay detecting IgG to the RBD and the Abbott Architect assay detecting IgG to the N protein. The neutralising antibody (NAb) titre was also determined for all samples with a virus neutralisation assay (VNA) using live virus. The positivity rate was 100% with the Wantai assay, 84.8% with the bioMerieux assay and 56.4% with the Abbott assay. Only 51% of HCWs were positive for the presence of NAb. Less than 10 % of HCWs NAb titer of 80. At a neutralising titer of 80, the area under the curves [IC 95%] was 0.71 [0.62-0.81], 0.75 [0.65-0.85] and 0.95 [0.92-0.97] for Wantai, Abbott and Vidas respectively. Commercial assays detecting antibodies against the N protein must not be used in long-term seroprevalence surveys while the Wantai assay could be very useful for this purpose. VNA should remain the gold standard to assess the protective antibody response, but some commercial assays could be useful for first-line screening of long-term presence of NAb.

To the Editor, 51

Since the SARS-CoV-2 emergence in December 2019, one of the major concerns is the duration of 52 immune protection after a first episode. This question is of paramount importance for healthcare 53 workers (HCWs) who are a highly exposed population and among the first targets of vaccination 54 programmes. To date, the persistence of SARS-CoV-2 antibodies in HCWs six months after disease 55 onset (ADO) has not been studied with both a virus neutralisation test and commercial assays. 56

HCWs who experienced COVID-19 during the early phase of the pandemic were included in a 57

prospective study conducted at the University Hospital of Lyon, France [1] . Serum samples 58 collected six months ADO were tested using three commercial assays: the Wantai Ab assay that 59 detects total antibodies against the receptor binding domain (RBD) of the S protein, the bioMérieux 60 was established on the basis of the median date of the RT-PCR positive result of the ward cluster. 67

All participants were tested positive for SARS-CoV-2 serology at least two weeks after disease 68 onset. The SARS-CoV-2 infection was also documented by RT-PCR test in 170 patients. 69

The positivity rate at six months ADO was 100% with the Wantai assay, 84.8% with the Vidas 70 assay, and 55.4% with the Architect assay. Only 51% of HCWs were positive for the presence of 71

NAb. Positive NAb titres ranged from 20 to 240. Only 27/296 (9.1%) had a NAb ≥ 80 ( Figure 1A ). 72

No difference in positivity rates with any assay was observed between patients with a SARS-CoV-2 73 infection documented by RT-PCR and the rest of the cohort. 74

Of the 296 HCWs, 6 (2.0%) developed a clinical form requiring hospitalisation; all were positive 75 with the three serological assays and for the presence of NAb with a median titre of 40 (range: 30-76 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 9, 2020. ; https://doi.org/10.1101/2020.12.08.20245811 doi: medRxiv preprint 160). By contrast, in asymptomatic HCWs, 8/8, 5/8, and 4/8 were positive with Wantai, Vidas, and 77

Architect assays, respectively, and only 3/8 exhibited NAbs with low titres (range: 30-60). 78

The area under the ROC curve (AUC) was estimated for assessing the performance of serological 79 assays for two NAb titres (PRNT 50 ≥ 20 or PRNT 50 ≥ 80; (Figure 1C , E, G Figure 1F) . 87

Among the 27 samples with NAb titre ≥ 80, all had a Vidas ratio above 8 compared to 31.5% and 88

3.5% of the samples with a titre between 20 and 80 or without NAb, respectively. 89

The findings of the present study indicate that, six months after infection, NAbs were no longer 90 detected in about half of HCWs who presented mainly mild COVID-19. Overall, the detection of 91 SARS-CoV-2 Abs with commercial tests was higher despite important heterogeneity between the 92 assays evaluated herein. In a previous study [3] , about 40% of asymptomatic subjects became 93 negative for IgG to the N protein within 3 to 6 months, which is consistent with that presented 94 herein for the Architect assay. This suggests that assays detecting only antibodies against the N 95 protein must not be used in long-term seroprevalence surveys. By contrast, the Wantai assay could 96 be very useful for epidemiological purposes as 100% of the HCWs were still positive at 6 months 97 ADO. Although VNA should remain the gold standard to assess the protective antibody response, 98 the data presented herein suggest that some commercial assays could be useful for first-line 99 screening of long-term presence of NAb as previously reported within 4 months ADO [2,4]. 100

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 9, 2020. ; https://doi.org/10.1101/2020.12.08.20245811 doi: medRxiv preprint Despite these observations on the decrease of NAbs in patients with mild COVID-19, it is important 101 to note that they do not preclude the protective role of an anamnestic antibody response in 102 previously exposed subjects, nor that of the long-term cellular immunity [5] .

We thank all the personnel of the occupational health and medicine department of Hospices Civils . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 9, 2020. ; https://doi.org/10.1101/2020.12.08.20245811 doi: medRxiv preprint 

Assessment of 105 serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, 106 multicentric study

109 Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of mild 110 COVID-19 patients: sensitivity, specificity and association with virus neutralization test

Orthogonal 113 SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and 114 Reveal Durable Humoral Immunity

Longitudinal 117 analysis of serology and neutralizing antibody levels in COVID19 convalescents

Functional 120 SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19